10-Q/A: SS Innovations International Restates Financials for Q2 2024 Amid Accounting Errors and Auditor Change
10-Q/A Amendment
SS Innovations International amended its Q2 2024 report to restate financial statements due to material errors and ineffective internal controls, following a change in auditors.
Summary
- SS Innovations International restated its previously issued interim unaudited condensed consolidated financial statements for the quarter ended June 30, 2024, due to material errors.
- The company's previous independent auditor, BF Borgers CPA PC, was barred from practicing before the SEC, leading to their dismissal and the engagement of BDO India LLP.
- BDO re-audited the company's consolidated financial statements for 2022 and 2023, and an internal review revealed material errors in prior filings.
- The company's disclosure controls and procedures and internal control over financial reporting were deemed ineffective as of June 30, 2024, due to material weaknesses.
- The restatement impacts Item 1 (Financial Statements), Item 2 (Management's Discussion and Analysis), Item 4 (Controls and Procedures) in Part I, and Item 1 (Legal Proceedings) in Part II of the original Form 10-Q.
- For the six months ended June 30, 2024, the company reported revenues of $8,146,819, comprising system sales of $7,752,957, instrument sales of $322,636, warranty sales of $38,202, and lease income of $33,024.
- The net loss for the six months ended June 30, 2024, was $13,982,323, compared to a net loss of $6,837,504 for the same period in 2023.
- The company's cash and cash equivalents as of June 30, 2024, were $608,215, with restricted cash totaling $5,947,187.
- The company has a working capital surplus of $8,291,143 and an accumulated deficit of $38,493,673 as of June 30, 2024, raising substantial doubt about its ability to continue as a going concern.
- Between February and April 2024, the company raised $4,450,000 through convertible promissory notes to finance working capital requirements.
- The company is addressing material weaknesses in internal controls by enhancing review processes, engaging external experts, and implementing a new ERP system.
Sentiment
Score: 3
Explanation: The sentiment is negative due to the restatement of financials, material weaknesses in internal controls, and concerns about the company's ability to continue as a going concern. While revenue increased, the significant net loss and accumulated deficit overshadow this positive aspect.
Positives
- Revenue increased to $8,146,819 for the six months ended June 30, 2024, compared to $2,261,933 for the same period in 2023, driven by increased system and instrument sales.
- The company is taking steps to remediate material weaknesses in internal controls by enhancing review processes and implementing a new ERP system.
- The company successfully raised $4,450,000 through convertible promissory notes to finance working capital requirements.
- Gross profit increased to $2,165,968 for the six months ended June 30, 2024, compared to $845,644 for the same period in 2023.
Negatives
- The company restated its Q2 2024 financials due to material accounting errors.
- Disclosure controls and procedures and internal control over financial reporting were deemed ineffective as of June 30, 2024.
- The company has an accumulated deficit of $38,493,673 as of June 30, 2024, raising concerns about its ability to continue as a going concern.
- The net loss for the six months ended June 30, 2024, was $13,982,323, significantly higher than the $6,837,504 loss in the same period of 2023.
Risks
- The company's ability to continue as a going concern is uncertain due to its accumulated deficit and dependence on raising additional capital.
- Material weaknesses in internal controls could lead to further financial misstatements or regulatory issues.
- The company faces risks related to scaling up operations, incurring capital expenditure, and financing research and development.
- The company is involved in litigation in the Bahamas regarding ownership of shares in an indirect subsidiary, which could result in financial losses or reputational damage.
Future Outlook
The company expects to require substantial funds for scaling up operations, incurring capital expenditure, and continuing research and development. The company plans to raise additional capital through further private or public offerings.
Management Comments
- Management is making efforts to raise further funding to scale up operations and meet its longer-term capital needs.
- Management believes that it will be successful in its capital formation and planned expansion of its operating activities, but there can be no assurance of this.
Industry Context
The company operates in the surgical robotics industry, which is experiencing increasing recognition of robotically assisted surgeries as an approved treatment modality. The company's financial performance is dependent on obtaining regulatory approvals in various regulated markets and increasing awareness of the benefits of robotically assisted surgery.
Comparison to Industry Standards
- The document does not provide specific comparisons to industry standards or comparable companies.
- Without specific benchmarks, it's difficult to assess the company's performance relative to industry peers such as Intuitive Surgical (ISRG), Stryker (SYK), or Medtronic (MDT).
- A thorough industry analysis would require comparing SS Innovations' revenue growth, profitability, and R&D spending to these established players.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Internal Control Weaknesses | Material weaknesses identified in disclosure controls and procedures and internal control over financial reporting. | June 30, 2024 | Ineffective controls could lead to further financial misstatements or regulatory issues. |
Legal Proceedings
- An ex-shareholder of Otto Pvt Ltd. commenced litigation in the Bahamas, seeking legal confirmation that it holds 9,000 shares (approximately a 9% interest) in Otto.
Related Party Transactions
- In April 2024, the company raised $2,000,000 from its affiliate by issuance of two One-Year 7% Promissory Notes of $1,000,000 each.
- Receivable from related party amounting to $1,286,980 and $1,567,559 as at June 30, 2024 and December 31, 2023 respectively, majorly consists proceeds of convertible promissory notes raised by the Company from the investors during the respective years, but collected by related entities on its behalf.
Stakeholder Impact
- Shareholders face potential dilution from future capital raises.
- Employees may be affected by cost-cutting measures if the company's financial situation does not improve.
- Customers may be concerned about the company's long-term viability and ability to provide ongoing support and maintenance for its products.
- Creditors face increased risk of non-payment if the company's financial situation deteriorates.
Next Steps
- The company is implementing a new ERP system to integrate all business functions within the accounting and financial department.
- The company is enhancing the review process for significant transactions to ensure proper accounting treatment.
- The company is engaging external experts where necessary to assist in the application of accounting principles to complex transactions.
- The company plans to raise additional capital through further private or public offerings.
Key Dates
| Date | Description |
|---|---|
| February 4, 2015 | SS Innovations International, Inc. was incorporated as AVRA Surgical Microsystems, Inc. |
| November 5, 2015 | The company's corporate name was changed to Avra Medical Robotics, Inc. (AVRA). |
| November 7, 2022 | Merger Agreement was executed among AVRA-SSI Merger Corporation, CardioVentures, and Dr. Sudhir Srivastava. |
| March 22, 2024 | The Company's Annual Report on Form 10-K filed with the SEC (the 2023 Form 10-K). |
| April 14, 2023 | The company consummated the acquisition of CardioVentures, Inc. |
| May 3, 2024 | The SEC entered an order barring BF Borgers CPA PC (Borgers) from appearing or practicing before the SEC. |
| May 13, 2024 | The company dismissed Borgers as its independent registered public accounting firm. |
| June 30, 2024 | End of the quarterly period for which financial statements are being restated. |
| October 12, 2024 | Dr. Srivastava and the Company entered into an Indemnification Agreement. |
| March 7, 2025 | There were 187,744,623 shares of common stock, $0.0001 par value of the Registrant issued and outstanding. |
| March 10, 2025 | Date of signatures for the Form 10-Q/A Amendment No. 1. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.